Join Our Webinar on Prostate Care

Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. MRI-targeted ultrasound-guided biopsies are the recommended methods for detection.
At Canon, we developed tailored solutions based on high-quality ultrasound imaging in combination with robust image fusion technology to perform transrectal and transperineal prostate biopsies quickly and effortlessly.

On June 13 (7 pm CEST / 1 pm EDT), during the webinar “Elevating Prostate Care: State-of-the-Art Ultrasound and Biopsy Solutions,” made possible by the Canon Medical Academy, all the techniques of MR/US fusion-guided biopsy will be presented, as well as additional technologies for multi-parametric ultrasound imaging of the prostate, and an outlook on potential applications for ultrasound-guided focal treatment will be discussed.

Watch the Webinar

Elevating Prostate Care: State-of-the-Art Ultrasound and Biopsy Solutions

Sign up for the webinar and join Prof. Thomas Fischer, Dr. Katrien Gieraerts, and Dr. Matthias Jahnen as they discuss state-of-the-art ultrasound and biopsy solutions.

  • Introduction | Prof. Thomas Fischer
  • Transperineal Fusion-Guided Prostate Biopsy Under Local Anaesthesia | Dr. Katrien Gieraerts
  • Summary of Current Guidelines and Insights for the Prospective Randomized FAST-Trial | Dr. Matthias Jahnen
  • Advanced Imaging of the Prostate and the Focal Therapy: Outlook and Initial Experience | Prof. Thomas Fischer
  • Live Q&A
Why Should You Attend?
  • Learn the value of MRI-fusion-guided biopsies for prostate
  • Get practical tips regarding transrectal and transperineal approaches
  • Understand the advantages of using advanced ultrasound techniques to evaluate the prostate
  • Participate in the live Q&A to find answers to your questions

All delegates will receive a certificate of attendance.

* Note: The full name entered by joining the live webinar will be used to generate your name on the attendance certificate.

Speakers and Presentations

Moderator and Speaker: Prof. Thomas Fischer, MD, PhD Radiologist, Head of Interdisciplinary Ultrasound Center,
Radiology, Executive Senior Physician, Department of Radiology
Charité University Medicine
Berlin, Germany

Presentation: Advanced Imaging of the Prostate and the Focal Therapy: Outlook and Initial Experience

Prostate cancer is the most common malignancy in men, and its incidence is continuously increasing. As with other malignant tumors, early and adequate diagnosis improves the chances of cure.
Patients who underwent organ-sparing treatment should be risk-stratified based on localization, extent, and actual Gleason score of the cancer. Real-time magnetic resonance imaging/ultrasound MRI/US-fusion-guided biopsy detects more clinically significant prostate cancers than conventional transrectal ultrasound (TRUS) biopsy. The aim of this session is to discuss state-of-the-art multi-parametric ultrasound techniques (mpUS) for MRI/US-fusion-guided biopsy in daily practice in comparison with transperineal MRI/US template or fusion biopsy, which has high sensitivity (>90%) in detecting aggressive prostate cancer.
Both techniques are useful in planning organ-sparing approaches (active surveillance, focal therapy).
In addition, we use SMI, shear-wave elastography, and ultrasound contrast agents to characterize focal prostate lesions and to monitor irreversible electroporation (IRE).
Discover More About the Moderator and Speaker

Speaker: Dr. Katrien Gieraerts, MD Radiologist
AZ Sint-Jan Brugge AV
Bruges, Belgium

Presentation: Transperineal Fusion-Guided Prostate Biopsy Under Local Anaesthesia

MRI/ultrasound fusion-guided prostate biopsies in the transperineal approach have become the recommended biopsy procedure according to the guidelines of the European Association of Urology (EAU).
We established in our department a streamlined and timesaving protocol for this approach under local anaesthesia on a Canon Aplio i800 ultrasound scanner.
We have performed more than 500 biopsies with very good tolerance by the patients and a high detection rate for clinically significant cancers.
Discover More About the Speaker

Speaker: Dr. Matthias Jahnen, MD Urology, Senior Resident
University Hospital Rechts der Isar, Technical University Munich
Munich, Germany

Presentation: Summary of Current Guidelines and Insights for the Prospective Randomized FAST-Trial

Current international guidelines recommend further diagnostic evaluation with prostate biopsy in men with suspicious mpMRI.
Given that, 5-10% of clinically significant PCa (defined as ≥ ISUP 2 PCa) may be missed by MRI-targeted biopsy alone, an additional 10-12 cores of systematic biopsy are still recommended and routinely performed in all biopsy-naïve patients.
The combination of systematic and MRI-targeted biopsy typically results in more than 12 and up to 25 biopsy cores, potentially increasing the risk of complications, discomfort, and peri-prostatic fibrosis. Therefore, strategies to reduce the number of biopsy cores have been increasingly investigated and are warranted.
Interim data from the FAST trial show that frozen section-assisted targeted prostate biopsy is feasible in men with suspicious mpMRI and provides rapid and reliable pathology results, allowing many men to avoid systematic biopsy.
Discover More About the Speaker

Other webinars that may interest you

Ultrasound Webinars


  • The opinions expressed in this material are solely those of the presenter and not necessarily those of Canon Medical Systems. Canon Medical Systems does not guarantee the accuracy or reliability of the information provided herein.
  • The clinical results, performance and views described in this video/webinar are the experience of the clinician. Results may vary due to clinical setting, patient presentation and other factors. Many factors could cause the actual results and performance of Canon Medical’s products to be materially different from any of the aforementioned.
  • Some products shown might not be available in all regulatory jurisdictions, please consult with your local Canon sales office for availability in your region.

Contact Us